

# CONFERENCE AGENDA



H. Lee Moffitt Cancer Center  
& Research Institute  
*An NCI Comprehensive Cancer Center*

*Presents*

*Molecular Targets in Cancer Therapy:  
Fourth Biennial Meeting*

*Mechanism  
and  
Therapeutic Reversal  
of Immune  
Suppression in Cancer*

*January 25 – 28, 2007*



*Sheraton Sand Key Resort  
Clearwater Beach, Florida*

*Jointly Sponsored by:*



## Conference Agenda

### 4<sup>th</sup> Biennial Molecular Targets in Cancer Therapy: Mechanism & Therapeutic Reversal of Immune Suppression in Cancer

January 25-28, 2007

Sheraton Sand Key Resort, Clearwater Beach, Florida

| <b>Thursday, January 25, 2007</b>  |          |
|--|----------|
| Registration begins at 3 p.m.  | Lobby 3  |
| 6 p.m. – 7:45 p.m.   |          |
| <b>Welcome Dinner and Opening Remarks</b>  | Palm/Bay |
| <i>D. Gabrilovich, MD, PhD, Organizing Committee Chair, H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa</i><br><i>W. Dalton, PhD, MD, Director and CEO, H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa</i><br><i>W. J. Pledger, PhD, Deputy Center Director, H. Lee Moffitt Cancer Center &amp; Research Institute</i><br><i>M. Foti, Chief Operating Officer, American Association for Cancer Research, Philadelphia</i> |          |
| 7:45 – 8:30 p.m.   |          |
| <b>Keynote Lecture</b>   | Palm/Bay |
| Chairperson: W. Dalton, PhD, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa  |          |
| Checkpoint Blockade in Cancer Immunotherapy<br><i>James P. Allison, PhD, Memorial Sloan Kettering Cancer Center, New York</i>  |          |
| 8:30 – 9:30 p.m.   |          |
| <b>Session 1: Cancer Immunotherapy – Successes and Challenges</b>  | Palm/Bay |
| Chairperson: W. Dalton, PhD, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa  |          |
| A Dendritic Cell Vaccine with p53 as the Tumor Antigen for Small Cell Lung Cancer<br><i>Scott Antonia, MD, PhD, H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa</i>   |          |
| Tipping the Immune System Balance in Favor of Effective Anti-Cancer Therapy<br><i>Elizabeth Jaffee, MD, Johns Hopkins University, Baltimore</i>  |          |

## Friday, January 26, 2007

|   |                     |
|---|---------------------|
| Registration begins at 7 a.m.   | Lobby 3             |
| 7:00 – 8:00 a.m.  |                     |
| Breakfast   | Palm/Bay            |
| 8:00 – 10:00 a.m.   |                     |
| <b>Session 2: Antigen Presenting Cells &amp; Immune Suppression:<br/>Mechanisms of T-Cell Non-Responsiveness</b>  | Island Ballroom     |
| Chairperson: J. Mulé, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa   |                     |
| Regulatory T-Cells and Cancer<br><i>Hy Levitsky, MD, Johns Hopkins University, Baltimore</i>  |                     |
| Programming of CD+8 T-Cell Tolerance<br><i>Stephen Schoenberger, PhD, La Jolla Institute for Allergy &amp; Immunology, San Diego</i>                            |                     |
| The B7 Family Molecules in Cancer Evasion<br><i>Lieping Chen, MD, PhD, Johns Hopkins University, Baltimore</i>  |                     |
| T Regulatory Cells and AICD: Two Intrinsic Mechanisms for Immune Suppression<br><i>Bijay Mukherji, MD, University of Connecticut Health Center, Farmington</i>  |                     |
| 10:00 – 10:30 a.m.  |                     |
| Break   | Palm/Bay            |
| 10:30 – 12:30 p.m.  |                     |
| <b>Session 3: Dual Roles of Dendritic Cells and Cancer</b>  | Island Ballroom     |
| Chairperson: S. Antonia, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa  |                     |
| T-Cell Regulation by Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase (IDO)<br><i>Andrew Mellor, PhD, Medical College of Georgia, Augusta</i>             |                     |
| Molecular Mechanisms of Negative Signaling by Cancer Associated HPV in Immune Escape<br><i>W. Martin Kast, PhD, University of South California, Los Angeles</i> |                     |
| Antigen Presenting Cells in Human Tumor Microenvironment<br><i>Weiping Zou, MD, PhD, Tulane University, New Orleans</i>   |                     |
| Mechanisms of Dendritic Cell Dysfunction in Cancer<br><i>Michael Shurin, MD, PhD, University of Pittsburgh, Pittsburgh</i>                                      |                     |
| 12:30 – 1:30 p.m.   |                     |
| Lunch   | Rusty's Dining Room |

|  |                 |
|--|-----------------|
| 1:40 – 4:00 p.m.   |                 |
| <b>Session 4: Cellular and Molecular Mechanisms of Immune Suppression in Cancer</b>  | Island Ballroom |
| Chairperson: J. Djeu, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa  |                 |
| <p>Regulation and Therapeutic Inhibition of IDO in Cancer<br/><i>George C. Prendergast, PhD, Lankenau Institute for Medical Research, Wynnewood</i></p> <p>Dual Roles of CD40 in the Development of Tumor-Specific T-Regulatory Cells and its Potential Use in Immune Therapy for Cancer<br/><i>Shu-Hsia Chen, PhD and Ping-Ying Pan, PhD, Mount Sinai School of Medicine, New York City</i></p> <p>Role of Antigen-Processing Machinery in the In Vitro Resistance of Squamous Cell Carcinoma of the Head and Neck Cells to Recognition by CTL<br/><i>Andres Lopez, MD, University of Pittsburgh Cancer Institute, Pittsburgh</i></p> <p>Targeting the Tumor Microenvironment with CpG-ODN Modifies Suppressor Cells Within the Tumor Resulting in Tumor Rejection<br/><i>Joseph Lustgarten, PhD, Mayo Clinic Arizona, Scottsdale</i></p> <p>Tumor-Secreted Factors Induce Normal Endothelial Cells to Inhibit Immune Cell Functions<br/><i>Jennifer Mulligan, Medical University of South Carolina, Charleston</i></p> <p>Tumor-Induced CD4+CD25+ Regulator T-Cells Dampen Effective Anti-Tumor Activity<br/><i>Zhaoyang You, PhD, University of Pittsburgh, Pittsburgh</i></p> <p>Recognition and Elimination of Tumor-Promoting Myeloid Cells by CD8+ CTL Cells Lead to Potent Inhibition of Tumor Growth<br/><i>Bin Zhang, MD, University of Chicago, Chicago</i></p> |                 |
| 1:40 – 9:30 p.m.   |                 |
| Poster Session   | Palm/Bay        |
| 4:00 – 5:00 p.m.   |                 |
| Poster Authors 1-40 available for questions  | Palm/Bay        |
| 6:30 – 8:00 p.m.   |                 |
| Dinner   | Gulf/Beach      |
| 8:00 – 9:30 p.m.   |                 |
| <b>Session 5: Cancer Immunotherapy – Successes and Challenges</b>  | Island Ballroom |
| Chairperson: V. Sondak, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa   |                 |

|  |                 |
|--|-----------------|
| <p>Autoimmunity and Vaccination in Melanoma<br/><i>Jeff Weber, MD, PhD, University of Southern California, Los Angeles</i></p> <p>Dendritic Cells as Vectors and Targets in Cancer Immunotherapy<br/><i>Anna Karolina Palucka, MD, PhD, Baylor Institute of Immunology Research, Dallas</i></p> <p>Targeting the CD40 Pathway for Cancer Therapy<br/><i>Robert H. Vonderheide, MD, DPhil, University of Pennsylvania School of Medicine, Philadelphia</i></p>  |                 |
| <b>Saturday, January 27, 2007</b>  |                 |
| Registration begins at 7 a.m.  | Lobby 3         |
| 7:00 – 8:00 a.m.   |                 |
| Breakfast  | Palm/Bay        |
| 8:00 – 10:00 a.m.  |                 |
| <b>Session 6: Immature Myeloid Suppressive Cells &amp; Tumor Escape</b>  | Island Ballroom |
| Chairperson: M. Fishman, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa   |                 |
| <p>T-Cell Tolerance Induced by Immature Myeloid Cells<br/><i>Dmitry Gabrilovich, MD, PhD, H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa</i></p> <p>Inflammatory Monocytes Induced by Tumors Alter T-Lymphocyte Responsiveness through L-Arginine Metabolism<br/><i>Vincenzo Bronte, MD, University of Padua, Padua</i></p> <p>Arginine Availability Regulates the Immune Response in Cancer Patients<br/><i>Augusto Ochoa, MD, Louisiana State University, New Orleans</i></p> <p>Immune Suppression and Inflammation in Tumor Progression<br/><i>Suzanne Ostrand-Rosenberg, PhD, University of Maryland, Baltimore</i></p> |                 |
| 10:00 – 10:30 a.m.   |                 |
| Break  | Palm/Bay        |
| 10:30 – 12:30 p.m.   |                 |
| <b>Session 7: The Role of Tumor Microenvironment in Tumor Escape</b>   | Island Ballroom |
| Chairperson: E. Sotomayor, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa  |                 |
| Cross-Targeting to Destroy the Tumor Microenvironment  |                 |

|  |                     |
|--|---------------------|
| <p><i>Hans Schreiber, MD, PhD, University of Chicago, Chicago</i></p> <p>Expression of Indoleamine 2,3-Dioxygenase by Tumor Cells as an Immune Resistance Mechanism That Can Be Fought<br/><i>Benoit Van den Eynde, MD, PhD, Ludwig Institute for Cancer Research, Brussels, Belgium</i></p> <p>Human Tumor Antigens, Tumor Immunosurveillance and Tumor Escape<br/><i>Olivera J. Finn, PhD, University of Pittsburgh, Pittsburgh</i></p> <p>IDO, Cross-Presentation and Tolerance<br/><i>David Munn, MD, Medical College of Georgia, Augusta</i></p>  |                     |
| 12:30 – 1:30 p.m.  |                     |
| Lunch  | Rusty's Dining Room |
| 1:40 – 4:00 p.m.   |                     |
| <b>Session 8: Cellular and Molecular Mechanisms of Immune Suppression in Cancer</b>  | Island Ballroom     |
| Chairperson: E. Celis, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa   |                     |
| <p>Bringing Immune Response to Tumor Sites to Generate CTL for Metastasis<br/><i>Yang-Xin Fu, MD, PhD, University of Chicago, Chicago</i></p> <p>TGF-Beta Inhibition Augments Immunogene Therapy and Adoptive Transfer of Lymphocytes<br/><i>Steven Albelda, MD, University of Pennsylvania, Philadelphia</i></p> <p>Mammary Tumor-Associated Growth Factor Overexpression and Expansion of Immature Myeloid Suppressor Cells<br/><i>Moses Donkor, University of Nebraska Medical Center, Omaha</i></p> <p>Reversing Tumor Immune Suppression with Intra-tumoral IL-12: Activation of Tumor-Associated T-Effector/Memory Cells and Induction of T-Suppressor Apoptosis<br/><i>Nejat Egilmez, PhD, University of Louisville, Louisville</i></p> <p>Combined Chemoimmunotherapy Can Efficiently Break Self-Tolerance and Induce Anti-Tumor Immunity in a Tolerogenic Murine Tumor Model<br/><i>Chang-Yui Kang, PhD, National University of Seoul, Seoul</i></p> <p>Vaccination with Leukemia Cells Expressing Cell Surface-Associated GM-CSF Blocks Leukemia Induction in Immunocompetent Mice<br/><i>Xiaoyang Ling, PhD, M.D. Anderson Cancer Center, Houston</i></p> |                     |

|  |                 |
|--|-----------------|
| Development of Adenoviral Vectors Interfering with the Jak/STAT Pathway to Overcome Tumor Induced DC Suppression<br><i>Dinja Oosterhoff, PhD, VU University Medical Center, Amsterdam</i>    |                 |
| 1:40 – 9:30 p.m.   |                 |
| Poster Session   | Palm/Bay        |
| 4:00 – 5:00 p.m.   |                 |
| Poster Authors 41-76 available for questions   | Palm/Bay        |
| 6:30 – 8:00 p.m.   |                 |
| Dinner   | Gulf Beach      |
| 8:00 – 9:00 p.m.   |                 |
| <b>Session 9: Cancer Immunotherapy – Successes and Challenges</b>  | Island Ballroom |
| Chairperson: A. Sloan, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa  |                 |
| Adoptive T-Cell Therapy of Renal Cell Cancer<br><i>Alfred Chang, MD, University of Michigan, Ann Arbor</i>   |                 |
| Disruption of Regulatory Pathways to Enhance the Efficacy of Cancer Vaccines<br><i>Johannes Vieweg, MD, FACS, University of Florida College of Medicine, Gainesville</i>                     |                 |
| <b>Sunday, January 28, 2007</b>  |                 |
| Registration begins at 7 a.m.  | Lobby 3         |
| 7:00 – 8:00 a.m.   |                 |
| Breakfast  | Lobby 3         |
| 8:00 – 10:00 a.m.  |                 |
| <b>Session 10: Molecular Mechanisms of Negative Signaling in Tumor Escape</b>  | Island Ballroom |
| Chairperson: C. Anasetti, MD & S. Dessureault, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa   |                 |
| Targeting Signaling Pathways in Antigen Presenting Cells to Overcome Tolerance to Tumor Antigens<br><i>Eduardo Sotomayor, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa</i> |                 |
| Antigen Presentation Attenuators and Anti-Tumor Immunity   |                 |

|   |                     |
|---|---------------------|
| <p><i>Si-Yi Chen, MD, PhD, Baylor College of Medicine, Houston</i></p> <p>Cancer Immunoediting: Basic Mechanisms and Therapeutic Implications<br/><i>Robert Schreiber, PhD, Washington University, St. Louis</i></p> <p>Promotion of a Type-1 Cell Response in Metastatic RCC Patients by SU11248; Modulation of a T-Reg Population<br/><i>Jim Finke, PhD, Cleveland Clinic Foundation, Cleveland</i></p>   |                     |
| 10:00 – 10:30 a.m.  |                     |
| Break   | Lobby 3             |
| 10:30 – 1:00 p.m.   |                     |
| <b>Session 11: Regulatory T-Cells &amp; Tumor Escape</b>  | Island Ballroom     |
| Chairperson: R. Wiltrot, PhD, National Cancer Institute, Bethesda   |                     |
| <p>Regulatory T-Cells<br/><i>Alexander Rudensky, PhD, University of Washington, Seattle</i></p> <p>Regulatory T-Cells in Cancer<br/><i>Tyler Curiel, MD, MPH, San Antonio Cancer Center, San Antonio</i></p> <p>Inhibiting T-Reg Activity in Tumor Bearers<br/><i>Mario P. Colombo, PhD, Istituto Nazionale Tumori, Milan</i></p> <p>Role of STAT3 in Mediating a Cross Talk Between Tumor and Regulatory T-Cells<br/><i>Hua Yu, PhD, Beckman Research Institute at City of Hope National Medical Center, Duarte</i></p> <p>Regulatory NKT Cells in Tumor Immunosurveillance and Cancer Vaccines<br/><i>Jay Berzofsky, MD, PhD, Center for Cancer Research, NCI, Bethesda</i></p> |                     |
| 1:00 – 2:00 p.m.  |                     |
| Lunch   | Rusty's Dining Room |
| 2:00 – 4:00 p.m.  |                     |
| <b>Session 12: Round Table Discussion: The Mechanism of Tumor Immune Suppression and Potential Approaches to Their Targeting/Closing Remarks</b>  | Island Ballroom     |
| Participants will include representatives from biotech and pharmaceutical companies, as well as the FDA and NCI to help expedite clinical trials that will produce meaningful benefits to cancer patients.  |                     |